Effect of homocysteine-lowering treatment with folic acid plus vitamin B6 on progression of subclinical atherosclerosis: a randomised, placebo-controlled trial

摘要: Summary Background A high plasma homocysteine concentration is associated with increased risk of atherothrombotic disease. We investigated the effects homocysteine-lowering treatment (folic acid plus vitamin B 6 ) on markers subclinical atherosclerosis among healthy siblings patients premature Methods did a randomised, placebo-controlled trial 158 167 80 were assigned placebo and 78 5 mg folic 250 daily for 2 years. The primary endpoint was development or progression as estimated from exercise electrocardiography, ankle-brachial pressure index, carotid femoral ultrasonography. Findings Ten participants in group, 14 group dropped out. Vitamin treatment, compared placebo, decrease fasting (from 14·7 to 7·4 μmol/L vs 12·0 μmol/L), postmethionine 64·9 34·9 64·8 50·3 μmol/L). It also decreased rate abnormal electrocardiography tests (odds ratio 0·40 [0·17–0·93]; p=0·035). There no apparent effect indices (0·87 [0·56–1·33]), peripheral-arterial outcome variables (1·02 [0·26–4·05] 0·86 [0·47–1·59], respectively). Interpretation Homocysteine-lowering disease occurrence tests, which consistent atherosclerotic coronary events.